Cerevel Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2018-01-01
- Employees
- -
- Market Cap
- $8.1B
- Website
- https://www.cerevel.com/
Clinical Trials
48
Active:24
Completed:23
Trial Phases
2 Phases
Phase 1:46
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (47 trials with phase data)• Click on a phase to view related trials
Phase 1
46 (97.9%)Phase 3
1 (2.1%)A Trial to Assess the Absorption, Metabolism, Excretion, and Mass Balance of [14C]-Darigabat After a Single Oral Dose in Healthy Male Participants
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 8
- Registration Number
- NCT06435923
- Locations
- 🇺🇸
Austin, Texas, Austin, Texas, United States
A Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Emraclidine in Healthy Adult Participants
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT06366243
- Locations
- 🇺🇸
Dilworth, Minnesota, Dilworth, Minnesota, United States
A Study to Assess Mass Balance, Pharmacokinetics, Metabolism, and Excretion of Emraclidine in Healthy Adult Male Participants
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 8
- Registration Number
- NCT06301971
- Locations
- 🇺🇸
Austin, Texas, Austin, Texas, United States
A Trial to Evaluate the Effects of Itraconazole and Carbamazepine on the Pharmacokinetics of Emraclidine and of Emraclidine on the Pharmacokinetics of Metformin in Healthy Adult Participants
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT05965219
- Locations
- 🇺🇸
Overland Park, Kansas, Overland Park, Kansas, United States
A Study Evaluating the Pharmacokinetics and Relative Bioavailability of Emraclidine Immediate-Release Tablets in Healthy Adult Participants
Phase 1
Completed
- Conditions
- Healthy Participants
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 15
- Registration Number
- NCT05933187
- Locations
- 🇺🇸
Overland Park, Kansas, Overland Park, Kansas, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
No news found